AstraZeneca PLC (AZN)vsAlpha Teknova Inc (TKNO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
TKNO
Alpha Teknova Inc
$3.55
+9.91%
HEALTHCARE · Cap: $175.31M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 144863% more annual revenue ($58.74B vs $40.52M). AZN leads profitability with a 17.4% profit margin vs -42.6%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+34.3%
Fair Value
$3.24
Current Price
$3.55
$0.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -22.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity, Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while TKNO is a turnaround play — different risk/reward profiles.
TKNO carries more volatility with a beta of 0.33 — expect wider price swings.
TKNO is growing revenue faster at 7.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.4% margins. TKNO offers better value entry with a 34.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a prominent player in the synthetic biology sector, providing essential biological reagents and supplements that support life sciences research and biomanufacturing. The company meets critical demands in areas such as vaccine development, cell and gene therapy, and diagnostic testing, driven by a dedication to quality and outstanding customer service. Leveraging its strong biotechnology foundation and an unwavering focus on innovation, Alpha Teknova is strategically positioned to seize growth opportunities in the rapidly evolving life sciences market, thereby enhancing value for its investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?